July 7 (Reuters) - Medical device maker Trinity Biotech plc said U.S. health regulators approved its blood-clot analyzer, Destiny Max, sending its shares soaring 28 percent to a new 52-week high. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results